ElectroCore Inc

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ElectroCore reports record revenue growth and strategic expansion plans

ElectroCore's Q1 2024 earnings call showcased impressive revenue growth, strong gross margins, and successful product launches, underlining the company's market resilience and innovation capabilities. With a focus on strategic expansion and profitability, ElectroCore is well-positioned for sustained growth and market leadership.
While facing challenges in managing R&D expenses and optimizing product returns, ElectroCore's commitment to operational efficiency and market diversification mitigates potential risks. The company's emphasis on employee contributions and customer relationships reinforces its competitive edge and customer loyalty.
By capitalizing on opportunities to expand product offerings, enter new markets, and drive innovation, ElectroCore can unlock significant growth potential and solidify its position as a key player in the neuromodulation industry. Navigating challenges through strategic decision-making and market differentiation will be crucial for ElectroCore's future success.

ElectroCore reports record revenue and margin growth in Q2 2024

ElectroCore's Q2 2024 earnings call showcased exceptional financial performance, marked by record revenue, improved margins, and a notable reduction in net loss.
The company's strengths lie in its revenue growth, product innovation, and solid financial position, while facing challenges in certain product sales and market competition.
Opportunities for ElectroCore include expanding product reach, exploring new therapeutic areas, and leveraging its strong cash position for strategic investments and growth.
Overall, ElectroCore's performance reflects resilience and potential for sustained growth in the healthcare industry, supported by a strong financial foundation and innovative product pipeline.

ElectroCore reports robust Q3 revenue growth, eyes VA channel expansion

ElectroCore Inc delivered strong revenue growth and improved financial performance in Q3 2024, driven by key product sales and customer expansion.
While facing challenges in certain product lines and overall net loss, the company's strategic focus on growth areas and cost management bode well for the future.
Opportunities in new purchase orders, VA channel expansion, and brand development position ElectroCore for continued success and market advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

nVNS decreases certain biomarkers associated with the severity of COVID-19 through five days of treatment nVNS decreases certain biomarkers associated with the severity of COVID-19 through five days of treatment

electroCore Announces Top Line Results from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients

Health Canada has approved ElectroCore Inc's (NASDAQ: ECOR) gammaCore Sapphire family of products to prevent and treat migraine and cluster headache. GammaCore Sapphire will be distributed in Canada by RSK Medical Inc, under an exclusive distribution agreement announced in January this year.

ElectroCore's Stock Is Trading Higher After Its Nerve Stimulator Wins Canadian Approval For Migraine

ROCKAWAY, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Health Canada has granted regulatory approval for the promotion and sale of the gammaCore Sapphire family of products in Canada for prevention and therapeutic treatment of migraine and cluster headache, as outlined in the registration application with Health Canada.

electroCore, Inc. Announces Regulatory Approval in Canada

ROCKAWAY, N.J.--(BUSINESS WIRE)--Amid the vaccine roll out, 97,309 new cases of COVID-19 have been reported to the CDC. Peter Staats, M.D. Chief Medical Officer of electroCore, Inc. (Nasdaq: ECOR), outlines common COVID-19 symptoms and at-home steps that can be discussed with health care providers to reduce symptoms. At-home steps to reduce COVID-19 symptoms: Confusion and Brain Fog: Although brain fog is not a true medical condition, it is a common symptom for many COVID-19 patients. Confusion

Chief Medical Officer of electroCore, Inc. Peter Staats, M.D. Describes Potential At-Home Solutions to Reduce Common COVID-19 Symptoms

electroCore's (ECOR) CEO Dan Goldberger on Q4 2020 Results - Earnings Call Transcript

Full year 2020 net sales of approximately $3.5 million increased 46% over $2.4 million for full year 2019

electroCore Announces Fourth Quarter and Full Year 2020 Financial Results

ROCKAWAY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in two upcoming investor conferences.

electroCore to Participate at Two Upcoming Investor Conferences

Shares of electroCore, Inc. (NASDAQ: ECOR) were trading higher Monday following the company's announcement of an exclusive distribution agreement with Medistar following regulatory approval in Australia. Shares hit a high of $4.09 and a low of $2.06 during Monday's  premarket session.

Electrocore Shares Rally: Some Technical Levels For The Medtech Stock

ElectroCore (ECOR) stock is rocketing higher on Monday after announcing a distribution deal in Australia for its gammaCore Sapphire. The post ECOR Stock: The Deal That Has Medical Device Company ElectroCore Soaring Today appeared first on InvestorPlace.

ECOR Stock: The Deal That Has Medical Device Company ElectroCore Soaring Today

The Australian Therapeutic Goods Administration has approved ElectroCore Inc's (NASDAQ: ECOR) gammaCore Sapphire family of products, including a non-invasive vagus nerve stimulator (nVNS) for primary headache disorders. Concurrently, the company has entered into an agreement with Medistar2 PTY Limited, whereby Medistar will serve as the exclusive distributor of the gammaCore Sapphire nVNS in Australia.

ElectroCore's Shares Are Trading Higher After Australia Ok'd Vagus Nerve Stimulator For Headaches

The stock price of electroCore, Inc. (NASDAQ: ECOR) increased by over 70% pre-market. This is why it happened.

ECOR Stock Price Increases Over 70% Pre-Market: Why It Happened

ROCKAWAY, N.J., Feb. 28, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Medistar2 PTY Limited (“Medistar”) whereby Medistar will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Australia, supplying therapy to patients suffering with primary headache disorders. The announcement follows the granting of regulatory approval from the Australian Therapeutic Goods Administration (TGA) for the promotion and sale of the gammaCore Sapphire family of products.

electroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia

ElectroCore Inc (NASDAQ: ECOR) and the Hospital Clínico Universitario de Valencia in Spain have completed the enrollment in the SAVIOR-1 study. This study was supported in part by electroCore.

ElectroCore Concludes Enrollment In COVID-19 Study Evaluating Vagus Nerve Stimulation

The stock price of electroCore, Inc. (NASDAQ: ECOR) is trading at over 14% pre-market. This is why it happened.

ECOR Stock Price Increases Over 14% Pre-Market: Why It Happened

ROCKAWAY, N.J.--(BUSINESS WIRE)--electroCore,Inc.(Nasdaq: ECOR) closes patient enrollment study SAVIOR-1 to better understand clinical benefit of non-invasive vagus nerve stimulation

Non-Invasive Vagus Nerve Stimulation (nVNS) Enters New Stage of COVID-19 Research

Extension maintains listing through June 3, 2023 Extension maintains listing through June 3, 2023

electroCore Announces Two-Year Extension of gammaCore™ Listing in the NHS Supply Chain Catalogue

FDA clearance expands gammaCore label to include the acute and preventive treatment of migraine in adolescents 12 to 17 years of age FDA clearance expands gammaCore label to include the acute and preventive treatment of migraine in adolescents 12 to 17 years of age

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine

ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled: “Non-invasive vagus nerve stimulation to reduce ileus after major colorectal surgery: Early development study” in the journal Colorectal Disease. The paper reports on the results of a parallel group, randomized controlled trial conducted at St. James's University Hospital in Leeds, England. The study was funded by the Bowel Research UK supported by the National Institute for Health Research (NIHR) Surgical MedTech Co-operative.

electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Reduce Ileus After Major Colorectal Surgery

ROCKAWAY, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held virtually February 17-19, 2021.

electroCore to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke. TR-VENUS is a double blind, randomized, sham-controlled, multi-center clinical trial, conducted at nine major medical centers across Turkey, supported by the Turkish Neurological Society and partially funded through an unrestricted research grant from electroCore.

electroCore Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke

ROCKAWAY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with RSK Medical Inc. (“RSK Medical”) whereby RSK Medical will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Canada, supplying therapy to patients suffering with primary headache disorders.

electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada

The stock price of electroCore, Inc. (NASDAQ: ECOR) is trading at over 15% pre-market today. This is why it happened.

ECOR Stock Price Increases Over 15% Pre-Market: Why It Happened

ROCKAWAY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Health Improvement Scotland (“HIS”) has published a Scottish Health Technology Group (“SHTG”) adaptation for NHS Scotland on the use of gammaCore for cluster headache. The SHTG publication is based on guidance produced in 2019 by the U.K. National Institute for Health and Care Excellence (“NICE”), which states that gammaCore, when used alongside standard of care, can reduce the frequency and intensity of cluster headache attacks, leading to significant quality of life benefits for people living with this condition and can save an average of £450 per patient in the first year of treatment through a reduction in acute rescue medication use, and with electroCore offering no-cost evaluations for all patients. The SHTG publication recommends that gammaCore should be available for a 3-month trial period for use in treating NHS Scotland patients suffering from cluster headache and the SHTG adaptation will now be disseminated across NHS Scotland health boards by HIS, to inform the use of gammaCore for cluster headache.

electroCore, Inc. Announces Scottish Health Technology Group Recommendation For Use of gammaCore™ in NHS Scotland Cluster Headache Patients

ROCKAWAY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Centers for Medicare and Medicaid Services (“CMS”) published its most recent Level II Healthcare Common Procedure Coding System (“HCPCS”) decisions on January 15, 2021, establishing a unique code K1020 “Non-invasive vagus nerve stimulator.” The coding decision covers the Company's gammaCore Sapphire™ D and is in response to the application submitted by the Company during CMS' second biannual 2020 Coding Cycle for non-drug and non-biological items and services, which application focused on the clinical and economic advantages of gammaCore therapy. All final coding decisions for the second biannual 2020 Coding Cycle for non-drug and non-biological items and services will go into effect on April 1, 2021.

electroCore, Inc. Announces the Establishment of a Unique Level II HCPCS Code for “Non-Invasive Vagus Nerve Stimulator”

Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M; greater than 40% growth over full year 2019 revenue of $2.4M

News for ElectroCore Inc Stock (ECOR)